Novo Nordisk A/S (NVO)
43.06
-0.94
(-2.15%)
USD |
NYSE |
Sep 11, 16:00
43.06
0.00 (0.00%)
After-Hours: 16:29
Novo Nordisk Gross Profit (TTM) : 41.49B for June 30, 2026
Gross Profit (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 41.49B |
| March 31, 2026 | 41.67B |
| December 31, 2025 | 37.83B |
| September 30, 2025 | 38.25B |
| June 30, 2025 | 38.15B |
| March 31, 2025 | 36.76B |
| December 31, 2024 | 35.63B |
| September 30, 2024 | 33.30B |
| June 30, 2024 | 31.62B |
| March 31, 2024 | 30.06B |
| December 31, 2023 | 28.51B |
| September 30, 2023 | 25.91B |
| June 30, 2023 | 23.95B |
| March 31, 2023 | 22.20B |
| December 31, 2022 | 20.98B |
| September 30, 2022 | 20.45B |
| June 30, 2022 | 19.95B |
| March 31, 2022 | 19.37B |
| December 31, 2021 | 18.61B |
| September 30, 2021 | 17.92B |
| June 30, 2021 | 17.28B |
| March 31, 2021 | 16.55B |
| December 31, 2020 | 16.22B |
| September 30, 2020 | 15.97B |
| June 30, 2020 | 15.68B |
| Date | Value |
|---|---|
| March 31, 2020 | 15.74B |
| December 31, 2019 | 15.28B |
| September 30, 2019 | 15.12B |
| June 30, 2019 | 15.00B |
| March 31, 2019 | 14.90B |
| December 31, 2018 | 14.92B |
| September 30, 2018 | 14.76B |
| June 30, 2018 | 14.65B |
| March 31, 2018 | 14.55B |
| December 31, 2017 | 14.27B |
| September 30, 2017 | 14.16B |
| June 30, 2017 | 14.16B |
| March 31, 2017 | 14.13B |
| December 31, 2016 | 14.05B |
| September 30, 2016 | 14.04B |
| June 30, 2016 | 13.93B |
| March 31, 2016 | 13.81B |
| December 31, 2015 | 13.64B |
| September 30, 2015 | 13.53B |
| June 30, 2015 | 13.46B |
| March 31, 2015 | 13.32B |
| December 31, 2014 | 13.20B |
| September 30, 2014 | 13.08B |
| June 30, 2014 | 12.75B |
| March 31, 2014 | 12.57B |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| AstraZeneca PLC | 44.95B |
| Johnson & Johnson | 66.63B |
| Eli Lilly & Co. | 66.44B |
| Merck & Co., Inc. | 48.01B |
| Novartis AG | 40.59B |